News | December 13, 2021
ICMR Dibrugarh designs kit to detect Omicron variant in two hours
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
Collectively, these 10 laboratories are capable of processing about 10,000 samples in a day and deliver results within the given turnaround time
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
The Omicron variant, which was designated a variant of concern by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone
The company is marketing the kit under the brand name CoviFind and it can detect the infection in 15 minutes
.jpg)
Molbio Diagnostics has been the pioneer in providing access to molecular testing through its Truenat Real Time PCR platform. Sriram Natarajan, Director & CEO, of the company shares his experiences on the journey so far in an interview with Thomas C Thottathil
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021
The consideration for the acquisition is US $ 2.25 million
Subscribe To Our Newsletter & Stay Updated
